Stock Scorecard
Stock Summary for Context Therapeutics Inc (CNTX) - $2.32 as of 9/6/2024 10:03:19 PM EST
Total Score
13 out of 30
Currently on the following lists
Small Cap Stock List
Tim's Recommendation
Possible Buy
Growth List Algorithm Criteria for CNTX
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for CNTX
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for CNTX
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for CNTX
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Latest News for for CNTX
Financial Details for CNTX
Company Overview |
|
|---|---|
| Ticker | CNTX |
| Company Name | Context Therapeutics Inc |
| Country | USA |
| Description | Centrexion Therapeutics Corporation, a late-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of chronic pain. The company is headquartered in Boston, Massachusetts. |
| Sector Name | LIFE SCIENCES |
| Industry Name | PHARMACEUTICAL PREPARATIONS |
| Most Recent Quarter | 6/30/2024 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 2.32 |
| Last Day Price Updated | 9/6/2024 10:03:19 PM EST |
| Last Day Volume | 96,310 |
| Average Daily Volume | 82,773 |
| 52-Week High | 2.75 |
| 52-Week Low | 0.77 |
| Last Price to 52 Week Low | 201.30% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 34.82 |
| Sector PE | 80.12 |
| 5-Year Average PE | -2.79 |
| Free Cash Flow Ratio | 1.72 |
| Industry Free Cash Flow Ratio | 13.19 |
| Sector Free Cash Flow Ratio | 30.42 |
| Current Ratio Most Recent Quarter | 64.01 |
| Total Cash Per Share | 1.35 |
| Book Value Per Share Most Recent Quarter | 1.35 |
| Price to Book Ratio | 1.69 |
| Industry Price to Book Ratio | 6.02 |
| Sector Price to Book Ratio | 22.15 |
| Price to Sales Ratio Twelve Trailing Months | 0.00 |
| Industry Price to Sales Ratio Twelve Trailing Months | 7.56 |
| Sector Price to Sales Ratio Twelve Trailing Months | 6.66 |
Share Statistics |
|
| Total Shares Outstanding | 74,998,000 |
| Market Capitalization | 173,995,360 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Last Dividend Amount | 0.00 |
| Current Dividend Amount | 0.00 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -61.53% |
| Reported EPS 12 Trailing Months | -0.90 |
| Reported EPS Past Year | -0.27 |
| Reported EPS Prior Year | -1.50 |
| Net Income Twelve Trailing Months | -18,566,875 |
| Net Income Past Year | -23,964,211 |
| Net Income Prior Year | -14,835,939 |
| Quarterly Revenue Growth YOY | 0.00% |
| 5-Year Revenue Growth | 335.62% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 101,536,832 |
| Total Cash Past Year | 14,449,827 |
| Total Cash Prior Year | 35,497,445 |
| Net Cash Position Most Recent Quarter | 101,536,832 |
| Net Cash Position Past Year | 14,449,827 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 11,871,020 |
| Total Stockholder Equity Prior Year | 34,758,366 |
| Total Stockholder Equity Most Recent Quarter | 101,104,508 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -18,404,430 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.25 |
| Free Cash Flow Past Year | -21,047,618 |
| Free Cash Flow Prior Year | -13,586,070 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | False |
| Liquidity Rating | None |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.03 |
| MACD Signal | 0.07 |
| 20-Day Bollinger Lower Band | 1.51 |
| 20-Day Bollinger Middle Band | 2.09 |
| 20-Day Bollinger Upper Band | 2.68 |
| Beta | 2.31 |
| RSI | 44.62 |
| 50-Day SMA | 0.00 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 0.00 |
System |
|
| Modified | 9/6/2024 10:04:05 PM EST |